Résumé
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high-throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi-marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer.
langue originale | Anglais |
---|---|
Pages (de - à) | 271-288 |
Nombre de pages | 18 |
journal | Journal of Pathology |
Volume | 262 |
Numéro de publication | 3 |
Les DOIs | |
état | Publié - 1 mars 2024 |
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Journal of Pathology, Vol 262, Numéro 3, 01.03.2024, p. 271-288.
Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs
TY - JOUR
T1 - Image-based multiplex immune profiling of cancer tissues
T2 - translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer
AU - Jahangir, Chowdhury Arif
AU - Page, David B.
AU - Broeckx, Glenn
AU - Gonzalez, Claudia A.
AU - Burke, Caoimbhe
AU - Murphy, Clodagh
AU - Reis-Filho, Jorge S.
AU - Ly, Amy
AU - Harms, Paul W.
AU - Gupta, Rajarsi R.
AU - Vieth, Michael
AU - Hida, Akira I.
AU - Kahila, Mohamed
AU - Kos, Zuzana
AU - van Diest, Paul J.
AU - Verbandt, Sara
AU - Thagaard, Jeppe
AU - Khiroya, Reena
AU - Abduljabbar, Khalid
AU - Acosta Haab, Gabriela
AU - Acs, Balazs
AU - Adams, Sylvia
AU - Almeida, Jonas S.
AU - Alvarado-Cabrero, Isabel
AU - Azmoudeh-Ardalan, Farid
AU - Badve, Sunil
AU - Baharun, Nurkhairul Bariyah
AU - Bellolio, Enrique R.
AU - Bheemaraju, Vydehi
AU - Blenman, Kim R.M.
AU - Botinelly Mendonça Fujimoto, Luciana
AU - Burgues, Octavio
AU - Chardas, Alexandros
AU - Cheang, Maggie Chon U.
AU - Ciompi, Francesco
AU - Cooper, Lee A.D.
AU - Coosemans, An
AU - Corredor, Germán
AU - Dantas Portela, Flavio Luis
AU - Deman, Frederik
AU - Demaria, Sandra
AU - Dudgeon, Sarah N.
AU - Elghazawy, Mahmoud
AU - Fernandez-Martín, Claudio
AU - Fineberg, Susan
AU - Fox, Stephen B.
AU - Giltnane, Jennifer M.
AU - Gnjatic, Sacha
AU - Gonzalez-Ericsson, Paula I.
AU - Grigoriadis, Anita
AU - Halama, Niels
AU - Hanna, Matthew G.
AU - Harbhajanka, Aparna
AU - Hart, Steven N.
AU - Hartman, Johan
AU - Hewitt, Stephen
AU - Horlings, Hugo M.
AU - Husain, Zaheed
AU - Irshad, Sheeba
AU - Janssen, Emiel A.M.
AU - Kataoka, Tatsuki R.
AU - Kawaguchi, Kosuke
AU - Khramtsov, Andrey I.
AU - Kiraz, Umay
AU - Kirtani, Pawan
AU - Kodach, Liudmila L.
AU - Korski, Konstanty
AU - Akturk, Guray
AU - Scott, Ely
AU - Kovács, Anikó
AU - Lænkholm, Anne Vibeke
AU - Lang-Schwarz, Corinna
AU - Larsimont, Denis
AU - Lennerz, Jochen K.
AU - Lerousseau, Marvin
AU - Li, Xiaoxian
AU - Madabhushi, Anant
AU - Maley, Sai K.
AU - Manur Narasimhamurthy, Vidya
AU - Marks, Douglas K.
AU - McDonald, Elizabeth S.
AU - Mehrotra, Ravi
AU - Michiels, Stefan
AU - Kharidehal, Durga
AU - Minhas, Fayyaz ul Amir Afsar
AU - Mittal, Shachi
AU - Moore, David A.
AU - Mushtaq, Shamim
AU - Nighat, Hussain
AU - Papathomas, Thomas
AU - Penault-Llorca, Frederique
AU - Perera, Rashindrie D.
AU - Pinard, Christopher J.
AU - Pinto-Cardenas, Juan Carlos
AU - Pruneri, Giancarlo
AU - Pusztai, Lajos
AU - Rajpoot, Nasir Mahmood
AU - Rapoport, Bernardo Leon
AU - Rau, Tilman T.
AU - Ribeiro, Joana M.
AU - Rimm, David
AU - Vincent-Salomon, Anne
AU - Saltz, Joel
AU - Sayed, Shahin
AU - Hytopoulos, Evangelos
AU - Mahon, Sarah
AU - Siziopikou, Kalliopi P.
AU - Sotiriou, Christos
AU - Stenzinger, Albrecht
AU - Sughayer, Maher A.
AU - Sur, Daniel
AU - Symmans, Fraser
AU - Tanaka, Sunao
AU - Taxter, Timothy
AU - Tejpar, Sabine
AU - Teuwen, Jonas
AU - Thompson, E. Aubrey
AU - Tramm, Trine
AU - Tran, William T.
AU - van der Laak, Jeroen
AU - Verghese, Gregory E.
AU - Viale, Giuseppe
AU - Wahab, Noorul
AU - Walter, Thomas
AU - Waumans, Yannick
AU - Wen, Hannah Y.
AU - Yang, Wentao
AU - Yuan, Yinyin
AU - Bartlett, John
AU - Loibl, Sibylle
AU - Denkert, Carsten
AU - Savas, Peter
AU - Loi, Sherene
AU - Specht Stovgaard, Elisabeth
AU - Salgado, Roberto
AU - Gallagher, William M.
AU - Rahman, Arman
N1 - Publisher Copyright: © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
PY - 2024/3/1
Y1 - 2024/3/1
N2 - Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high-throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi-marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer.
AB - Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high-throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi-marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer.
KW - cancer prognosis
KW - clinical integration
KW - digital image analysis
KW - multiplex imaging
KW - multiplex immunofluorescence
KW - multiplex immunohistochemistry
KW - therapy response
KW - tumour immune profiling
KW - tumour infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85182480446&partnerID=8YFLogxK
U2 - 10.1002/path.6238
DO - 10.1002/path.6238
M3 - Review article
AN - SCOPUS:85182480446
SN - 0022-3417
VL - 262
SP - 271
EP - 288
JO - Journal of Pathology
JF - Journal of Pathology
IS - 3
ER -